The Fragility of the Biopharmaceutical Industry: Unraveling the Shadows of Verbal Decoupling

In the realm of geopolitics and global economics, the biopharmaceutical industry has found itself entangled in a web of uncertainty and vulnerability. The recent threats of verbal decoupling have cast a shadow over the industry, raising questions about its resilience and the potential impact on major stakeholders. This article delves into the ramifications of such decoupling and explores the potential consequences for global healthcare and the key players involved.

The Biggest Losers: Who Will Bear the Brunt?
The multinational pharmaceutical companies, often considered the beneficiaries of globalization, hold a dominant position in China's innovative drug sector. However, they stand as the primary victims of comprehensive decoupling measures. For instance, in 2022, eight multinational pharmaceutical companies, including AstraZeneca, Merck, and Novartis, generated a combined pharmaceutical revenue of approximately $28.9 billion in the Chinese market. In contrast, 56 Hong Kong-listed biotech companies, excluding Kangxinuo, reported a total product revenue of $25.4 billion in 2022, projected to surpass $40 billion in 2023, still a fraction of foreign capital. The direct consequences of decoupling on multinational pharmaceutical companies are substantial.

China has emerged as the second-largest market for AstraZeneca, with the company's revenue in the country reaching $3.043 billion in the first half of 2023, accounting for 14% of its global performance. Similarly, Merck witnessed China becoming its third-largest market, with sales of $3.581 billion in the same period, approximately 2.5 times the sales of Hengrui Medicine and a 45% year-on-year growth. China also holds the position of the second-largest market for Sanofi, with sales of €728 million in Q3 2023. Companies like Novartis and Takeda have identified China as their second-largest target market. Furthermore, by the first half of 2023, seven Chinese Contract Development and Manufacturing Organizations (CDMOs) derived over 75% of their revenue from overseas operations. The logic behind this trend is the transfer of outsourced research and production orders from overseas pharmaceutical companies. The average industry pay in China is approximately half that of its developed counterparts, resulting in service fees that are only 30% to 60% of those charged by developed countries. If the CDMO supply chain were to be completely decoupled, multinational pharmaceutical companies would face a second wave of damage.

The Complexity of Global Pharmaceutical Supply Chains:
Attempting to sever the deeply integrated and interdependent global pharmaceutical industry is far more challenging than populist sentiments might suggest. The implications of disrupting the supply of cost-effective essential drugs would be severe and create a global challenge. The United States has already experienced drug shortages, as seen in the emergency procurement of platinum-based chemotherapy drugs from Chinese manufacturer Qilu Pharmaceutical in 2023. The packaging boxes didn't even have time to be translated into English. According to the National Cancer Institute, up to 20% of cancer patients rely on platinum-based chemotherapy drugs for treatment. This shortage resulted from the cessation of platinum material supply from an Indian factory due to quality issues. Around 90% of the generic drugs prescribed in the United States are sourced from India, highlighting the risks associated with dependence on a single supplier.

In 2022, the World Health Organization and health departments of various countries linked Indian cough syrups to the deaths of at least 141 children in Gambia, Uzbekistan, and Cameroon. In 2023, two eye drops produced in India caused three deaths and four cases of eye removal in the United States due to lack of sterilization. Another reason for drug shortages in the United States is the discontinuation of production by pharmaceutical companies of many life-saving non-patented drugs due to low profits, resulting in approximately 300 essential drugs being perpetually in short supply. One such drug is VinCristine, a low-profit essential medication for childhood leukemia, with each dose costing.